Explaining TPMT genotype/phenotype discrepancy by haplotyping of TPMT*3A and identification of a novel sequence variant, TPMT*23

被引:32
作者
Lindqvist, Malin [1 ]
Skoglund, Karin
Karlgren, Anna
Soderkvist, Peter
Peterson, Curt
Kidhall, Irene
Almer, Sven
机构
[1] Linkoping Univ, Fac Hlth Sci, Dept Med & Care, Div Clin Pharmacol, SE-58185 Linkoping, Sweden
[2] Linkoping Univ, Fac Hlth Sci, Dept Biomed & Surg, Div Cell Biol, Linkoping, Sweden
[3] Linkoping Univ, Fac Hlth Sci, Div Gastroenterol & Hepatol, Dept Mol & Clin Med, Linkoping, Sweden
[4] Danderyd Hosp, Dept Med, Div Gastroenterol & Hepatol, Stockholm, Sweden
关键词
haplotypes; single nucleotide polymorphism; thiopurine methyltransferase;
D O I
10.1097/FPC.0b013e3282ef642b
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Thiopurine methyltransferase (TPMT) is a polymorphic enzyme involved in the metabolism of thiopurine drugs. Owing to polymorphisms in the TPMT gene (TPMT*2-*22), the enzyme activity varies interindividually. Patients with reduced TPMT activity may develop adverse reactions when treated with standard doses of thiopurines. This work focuses on a TPMT genotype/phenotype discrepancy found in a patient during routine testing. The patient displayed very low TPMT enzyme activity and she was genotyped by pyrosequencing as being heterozygous for the 460G > A and 719A > G polymorphisms (TPMT*3A). Complete sequencing in combination with haplotyping of the TPMT gene revealed a novel sequence variant, 500C > G, on one allele and TPMT*3A on the other allele, giving rise to the novel genotype TPMT*3A/*23. When investigating the patient's relatives, they too had the TPMT*3A/*23 genotype in combination with low enzyme activity. We conclude that this novel variant allele affects enzyme activity, as the individuals carrying it had almost undetectable TPMT activity.
引用
收藏
页码:891 / 895
页数:5
相关论文
共 15 条
[1]   Pyrosequencing of TPMT Alleles in a general Swedish population and in patients with inflammatory bowel disease [J].
Haglund, S ;
Lindqvist, M ;
Almer, S ;
Peterson, C ;
Taipalensuu, J .
CLINICAL CHEMISTRY, 2004, 50 (02) :288-295
[2]   Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine [J].
Kaskas, BA ;
Louis, E ;
Hindorf, U ;
Schaeffeler, E ;
Deflandre, J ;
Graepler, F ;
Schmiegelow, K ;
Gregor, M ;
Zanger, UM ;
Eichelbaum, M ;
Schwab, M .
GUT, 2003, 52 (01) :140-142
[3]   Genetic polymorphism of thiopurine S-methyltransferase: Clinical importance and molecular mechanisms [J].
Krynetski, EY ;
Tai, HL ;
Yates, CR ;
Fessing, MY ;
Loennechen, T ;
Schuetz, JD ;
Relling, MV ;
Evans, WE .
PHARMACOGENETICS, 1996, 6 (04) :279-290
[4]  
LEE D, 1995, DRUG METAB DISPOS, V23, P398
[5]   Identification of two novel sequence variants affecting thiopurine methyltransferase enzyme activity [J].
Lindqvist, M ;
Haglund, S ;
Almer, S ;
Peterson, C ;
Taipalensu, J ;
Hertervig, E ;
Lyrenäs, E ;
Söderkvist, P .
PHARMACOGENETICS, 2004, 14 (04) :261-265
[6]  
Lindqvist Malin, 2006, Current Pharmacogenomics, V4, P285, DOI 10.2174/157016006778992813
[7]   SIFT: predicting amino acid changes that affect protein function [J].
Ng, PC ;
Henikoff, S .
NUCLEIC ACIDS RESEARCH, 2003, 31 (13) :3812-3814
[8]   Differences between children and adults in thiopurine methyltransferase activity and metabolite formation during thiopurine therapy:: Possible role of concomitant methotrexate [J].
Pettersson, B ;
Almer, S ;
Albertioni, F ;
Söderhäll, S ;
Peterson, C .
THERAPEUTIC DRUG MONITORING, 2002, 24 (03) :351-358
[9]   Thiopurine S-methyltransferase pharmacogenetics: variant allele functional and comparative genomics [J].
Salavaggione, OE ;
Wang, LW ;
Wiepert, M ;
Yee, VC ;
Weinshilboum, RM .
PHARMACOGENETICS AND GENOMICS, 2005, 15 (11) :801-815
[10]  
Schaeffeler Elke, 2006, Hum Mutat, V27, P976